Special Issue "Immunotherapy against Latent Infection and Cancer"
Deadline for manuscript submissions: 30 September 2022 | Viewed by 148
Interests: pulmonary infection biology; tumor immunology / immunotherapy (lung and pancreatic cancer)
Special Issues, Collections and Topics in MDPI journals
Despite extensive global efforts, infectious and tumor diseases remain a major cause of morbidity and mortality worldwide and require innovative therapies for their effective management. Both tumor and pathogens have succeeded in creating a comfortable environment within the host, suppressing the host's defenses by altering regulatory mechanisms while regulating the host's metabolic function to meet nutritional needs. Advances in cancer biology and pathogenesis over the last two decades have led to immunotherapy strategies that have revolutionized the treatment of latent infection and/or malignant tumors. Furthermore, accumulative clinical evidences suggest a high proclivity of cancer development in the patients suffering from latent bacterial/viral pathogens. This is associated with sabotage of host immunity which supports the opportunistic survival of pathogens and tumors and promotes pathogenesis of diseases. Increased polarization of effector immune cells, such as M1 macrophages and CD8+ CTL, promote Th2 bias in hosts and predispose hosts for the development of cancer. In view of this and poor treatment outcomes with traditional options, immunotherapy has emerged as the most promising treatment modality because adjust the host immune response required for clearance of pathogens and tumor while maintaining homeostasis. Strategies, such as adoptive cell immunotherapy, designing tumors, vaccines, antibodies, drug conjugates, immune checkpoint inhibitors, and adjuvants comprising of immunotherapy which is being practiced globally for managing idiopathic infectious/tumor diseases.
In view of high significance of the field, the main mandate of this Special Issue would be to discuss various cutting edge stretegies targeting latent bacterial infection and cancer. Articles which are addressing the mandate would be given priority however other submission would also be welcomed and given due consideration. With this we invite the submission to this Special Issues
Dr. Hridayesh Prakash
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- bacterial infection
- macrophage polarization
- Th2 bias
- epigentic programming